The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | FIBROMET preliminary results: metformin promising for primary MF
Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses the preliminary results from an open label phase 2 trial, FIBROMET, evaluating the effects of metformin on bone marrow fibrosis and disease progression in primary myelofibrosis (PMF) patients. Prof. Saad highlights how this re-use of an old drug would give a cheaper and more accessible treatment, and outlines the next steps for the study. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
